SOURCE: Global Communications

April 12, 2005 11:30 ET

U.S. BioDefense Sponsored "Business of Stem Cell Research" Conference to Discuss Business Opportunities

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Global Communications Inc.

FULLERTON, CA -- (MARKET WIRE) -- April 12, 2005 -- States looking to emulate the fertile ground that California has created for stem cell research have also provided a boost for stem cell research companies. News of proposed funding in the state of New York by the state's Senate and Assembly helped shares of StemCells (NASDAQ: STEM) and Aastrom Biosciences (NASDAQ: ASTM) jumped more than 15%, while shares of Geron (NASDAQ: GERN) added 7%.

New York follows the recently passed California State Proposition 71 providing $3 Billion in funding for embryonic as well as adult stem cell research with State funds of approximately $295 million annually for 10 years beginning with 2005. With the aid of the State, California should be a hotbed of scientific and technological advancements for the stem cell industry.

U.S. BioDefense, Inc. (OTC BB: UBDEE) recently published a white paper on Stem Cell technology transfer analyzing California University and industry participants intellectual property resources including ViaCell, Geron, Aastrom Biosciences, and StemCells, Inc. U.S. BioDefense is sponsoring the "Business of Stem Cell Research" Conference, produced by The Technology Council of Maryland and leading health care law firm Arent Fox, on April 25, 2005, at the Marriott Bethesda North Hotel & Conference Center in Rockville, Maryland, the first forum to bring together C-Level executives from industry, politics, academia and science to discuss the promise of stem cell research from a business perspective.

U.S. BioDefense is aggressively pursuing its Stem Cell Technology Transfer Initiative by licensing stem cell separation and insertion technology, filing a SBIR Grant proposal with the Department of Defense Chemical Biological Defense Agency for Stem Cell Technology and Autologous Bioengineered Skin, and by preparing to deploy an open source stem cell research and development collaboration platform to facilitate relationships among researchers, physicians, industry experts, and advisors.

About Global Communications, Inc.

Global Communications offers investor and market awareness services. Through proven techniques and a solid proprietary network of investors and professionals, Global Communications leverages its resources to maximize awareness and targeting return on investment. Global Communications, Inc. may have an equity position of up to 4.9% in the companies mentioned herein and may buy or sell the stock any time. Please visit our Section 17B disclaimer at www.globalcinc.com.

Contact Information